- Home
- ULBI vs CRDF Comparison
ULBI vs CRDF Comparison
Compare ULBI & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULBI
- CRDF
- Stock Information
- Founded
- ULBI 1990
- CRDF 1999
- Country
- ULBI United States
- CRDF United States
- Employees
- ULBI N/A
- CRDF N/A
- Industry
- ULBI Industrial Machinery/Components
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ULBI Miscellaneous
- CRDF Health Care
- Exchange
- ULBI Nasdaq
- CRDF Nasdaq
- Market Cap
- ULBI 158.1M
- CRDF 133.5M
- IPO Year
- ULBI 1992
- CRDF N/A
- Fundamental
- Price
- ULBI $7.74
- CRDF $2.62
- Analyst Decision
- ULBI Strong Buy
- CRDF Strong Buy
- Analyst Count
- ULBI 1
- CRDF 3
- Target Price
- ULBI $14.00
- CRDF $9.33
- AVG Volume (30 Days)
- ULBI 77.9K
- CRDF 972.3K
- Earning Date
- ULBI 11-08-2024
- CRDF 11-07-2024
- Dividend Yield
- ULBI N/A
- CRDF N/A
- EPS Growth
- ULBI 115.20
- CRDF N/A
- EPS
- ULBI 0.54
- CRDF N/A
- Revenue
- ULBI $165,152,000.00
- CRDF $688,000.00
- Revenue This Year
- ULBI $3.26
- CRDF $23.15
- Revenue Next Year
- ULBI $36.05
- CRDF N/A
- P/E Ratio
- ULBI $14.43
- CRDF N/A
- Revenue Growth
- ULBI 9.95
- CRDF 49.57
- 52 Week Low
- ULBI $6.36
- CRDF $1.21
- 52 Week High
- ULBI $13.39
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- ULBI 44.36
- CRDF 46.10
- Support Level
- ULBI $7.47
- CRDF $2.38
- Resistance Level
- ULBI $7.88
- CRDF $2.63
- Average True Range (ATR)
- ULBI 0.31
- CRDF 0.19
- MACD
- ULBI 0.06
- CRDF -0.04
- Stochastic Oscillator
- ULBI 70.65
- CRDF 26.42
About ULBI Ultralife Corporation
Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").